<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63692">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812837</url>
  </required_header>
  <id_info>
    <org_study_id>2821 50-5</org_study_id>
    <nct_id>NCT01812837</nct_id>
  </id_info>
  <brief_title>The Use of Microneedles in Photodynamic Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global aim of this study is to investigate how microneedles can facilitate the
      penetration and efficacy of photodynamic therapy in the treatment of actinic keratoses

      The specific aims are as follows:

        1. Investigate whether pretreatment with microneedles enhances penetration of topical
           aminolevulinic acid (ALA) that is marketed as Levulan® Kerasticks by DUSA
           pharmaceuticals Inc.

        2. Investigate whether pretreatment with microneedles can decrease the required incubation
           times of the topical ALA prior to exposure to blue light photodynamic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>complete response rate</measure>
    <time_frame>one month after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>20 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>60 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>60 minutes incubation - no pretreatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedle</intervention_name>
    <description>The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.</description>
    <arm_group_label>20 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>40 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>60 minutes incubation - with pretreatment</arm_group_label>
    <other_name>Microchannles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminolevulinic Acid</intervention_name>
    <description>Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA</description>
    <arm_group_label>20 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>40 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>60 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>60 minutes incubation - no pretreatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Blue light</intervention_name>
    <description>Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)</description>
    <arm_group_label>20 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>40 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>60 minutes incubation - with pretreatment</arm_group_label>
    <arm_group_label>60 minutes incubation - no pretreatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are 18 and older

          2. Subjects who have at least 3 actinic keratoses on each side of the forehead

          3. Subjects who signed an IRB approved informed consent

        Exclusion Criteria:

          1. Subjects who smoke

          2. Subjects who have a photosensitizing condition such as lupus, porphyria, or similar
             condition.

          3. Subjects who received a diagnosis of skin cancer on the face in past year

          4. Subjects who received field treatment for actinic keratoses to the face in the past
             60 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lam Nguyen, CCRP</last_name>
    <phone>916.734.6556</phone>
    <email>lam.nguyen@ucdmc.ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis, Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lambert Nguyen, CCRP</last_name>
      <phone>916-734-6556</phone>
      <email>lam.nguyen@ucdmc.ucdavis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ucdmc.ucdavis.edu/dermatology/</url>
    <description>UC Davis Dermatology Department</description>
  </link>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Daniel Eisen, MD</investigator_full_name>
    <investigator_title>Associate Clinical Professor of Dermatology, Director of Aesthetic Dermatology and Co-Director of Dermatologic Surgery</investigator_title>
  </responsible_party>
  <keyword>actinic keratosis</keyword>
  <keyword>microneedles</keyword>
  <keyword>photodynamic therapy</keyword>
  <keyword>levulan</keyword>
  <keyword>Aminolevulinic acid</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
